In total, 15 522 records were identified. After removal of duplicates, screening of title/abstracts for relevance and independent selection of full texts by two reviewers, 36 studies were included. Across all the included studies, 24 107 participants received a single one-off dose of gentamicin (doses ranged from 1 mg kg -1 to 480 mg per dose). Acute kidney injury was described in 2520 participants receiving gentamicin. The large majority of cases were reversible. There were no cases of ototoxicity reported in patients receiving gentamicin. A meta-analysis was not performed due to study heterogeneity.
Introduction
Gentamicin is a well-established antibiotic initially discovered in 1963 [1] , which is particularly useful for treating bacteria resistant to other antimicrobials. It is bactericidal and effective against Gram-negative and limited Gram-positive organisms. Gentamicin is not metabolized but distributed essentially unchanged within the extracellular space before excretion in the kidneys by glomerular filtration [2] . Its use is limited by potentially serious adverse effects, most commonly ototoxicity and nephrotoxicity.
Gentamicin was previously given as a multidose regimen each day, modified according to serum drug levels. Several studies have shown that single-daily dosing of gentamicin offers an equal, if not improved, toxicity profile [3] . However, the toxicity profile of a single one-off dose of gentamicin, as opposed to multiple doses over several days, remains unclear. A single dose is used as a prophylaxis prior to surgery or invasive procedures, such as endoscopic retrograde cholangio-pancreatography, and has also been proven to be effective in the treatment of gonorrhoea [4] [5] [6] . It is possible that a one-off dose is less toxic and may have a lower risk of adverse effects. Previous systematic reviews of gentamicin safety have focused on a specific indication for use [7] , drug preparation [8] , treatment population [9] , individual adverse effect [10] or dosing regimen [11] , but none have evaluated single-dose gentamicin. The aim of this systematic review was to assess the frequency and type of adverse events associated with the use of a single dose of intravenous or intramuscular gentamicin in adults.
Methods
A systematic review protocol was developed and registered with PROSPERO at the Centre for Reviews and Dissemination, University of York (Reg No. CRD42013003229 http:// www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD 42013003229).
Eligibility criteria
Studies were considered eligible for the review if they fulfilled the following criteria; human participants; male or female; age ≥16 years; intramuscular or intravenous gentamicin as a single one-off dose; control group; adverse effects monitored. The control group could comprise of any of the following: placebo; no treatment; or an antimicrobial regimen that did not include gentamicin. Including studies with one of these groups as a control allowed us to better identify the true adverse effects of single-dose gentamicin. If a study did not have a control group then it was not included in this review. For this reason, case studies, case reviews and some longitudinal studies were excluded based on the study design. No other restriction on study design was applied. There was no restriction on the indication for treatment, dose of gentamicin, length of follow-up, clinical setting in which gentamicin was given, year of publication or publication status.
Search strategy
The following electronic databases were searched: The Cochrane Library (including the Health Technology Assessment database); MEDLINE; EMBASE; British Nursing Index; and Cumulative Index Nursing and Allied Health Literature (CINAHL). The following were searched specifically for systematic reviews and guidelines: National Guideline Clearinghouse; National Institute for Health and Care Excellence; and Scottish Intercollegiate Guidelines Network. Ongoing trials were sought through the following trial registers: clinicaltrials.gov; World Health Organization International Clinical Trials Registry Platform and Current Controlled Trials. Conference abstracts and proceedings were searched using Zetoc and Conference Proceedings Citation Index, for all years available. Dissertations and theses were searched using ProQuest, Index to Theses in Great Britain and Ireland, and EThOS. Specific sources of drug information were searched, including pharmacovigilance data from regulatory authorities (electronic Medicines Compendium, US Food and Drug Administration, and Medicines and Healthcare products Regulatory Agency) and a specific drug bibliographic database (TOXLINE). Citation searching was carried out on included articles. To identify grey literature, the National Technical Information Service and OpenGrey were searched. Scoping searches were carried out to refine the search strategy. The initial search was carried out in the first week of February 2013, with an update search carried out in the first week of November 2016. An example of the search strategy used for one large database is available in Supplementary Information Appendix S1. Where the full search strategy could not be used, the word 'gentamicin' and its alternatives were searched for separately.
Study selection
All identified records were entered into Reference Manager Version 11.0 and duplicates removed. Titles and, where available, abstracts were screened by one reviewer for relevance, using the eligibility criteria. Due to the number of records it was not feasible for two independent reviewers to carry out this process but as a check for consistency 10% of records were randomly selected, using a random number generator, and screened independently by a second reviewer. Full text articles were sought for all potentially relevant records. Inclusion and exclusion criteria were applied to all full articles independently by two reviewers. Any disagreement between the two reviewers was resolved by discussion or by a third independent reviewer when necessary. Foreign language records were included when searching, and titles and abstracts were translated to allow screening. All potentially relevant foreign language studies were translated for assessment and, if appropriate, data extraction.
Data extraction
The data extraction form (Supplementary Information Appendix S2) was designed and piloted on five studies. Data extraction was carried out independently by two reviewers on all included studies. The following study characteristics were collected: (i) author; (ii) study design; (iii) country of publication; (iv) number of participants; (v) age range of participants; (vi) sex of participants; (vii) dose of gentamicin; and (viii) indication for gentamicin. Specific details about adverse events were collected for the gentamicin and control groups including: (i) number of participants; (ii) frequency of adverse events; (iii) type of adverse events; (iv) severity of adverse events; and (v) length of follow-up.
Risk of bias assessment
Risk of bias assessment was included within the data extraction form and was independently assessed by two reviewers. Risk of bias was assessed with a tool specific to the study design. Randomized trials were assessed using The Cochrane Collaboration's tool for assessing risk of bias. Nonrandomized trials were assessed using the NewcastleOttawa Scale for cohort studies or case-control studies, as appropriate. Specific risk of bias assessment for our outcome measure, adverse events, was carried out on all studies. This provided a common risk of bias assessment for all studies. For the risk of bias assessment of adverse events, we used questions recommended by the Cochrane Collaboration [12] [13] [14] .
Data synthesis
Characteristics, main findings and risk of bias assessment were tabulated for each study. If data were appropriate for meta-analysis, it was planned that results would be presented as a summary risk ratio with 95% confidence intervals, on an intention-to-treat basis.
Variations to protocol
In our published protocol, we planned to include studies comparing single one-off dose of gentamicin to a group receiving gentamicin in conjunction with other antimicrobials. To better identify genuine adverse effects of single-dose gentamicin, we later modified our protocol and excluded these studies.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [15] , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2015/16 [16] .
Results
The searches identified 15 522 records, of which 6858 were duplicates, leaving 8664 unique studies. Many of the duplicates were generated when searching TOXLINE database which generates a separate output for each search term (e.g. gentamicin, gentamycin and cidomycin). Due to the number of records, only one reviewer screened all the articles for relevance. A second reviewer screened 10% (n = 880) of the records to assess consistency and agreement between reviewers was moderate. When assessing the eligibility of full-text articles, we found that some studies recruited both children and adults but none provided separate analysis by age group. Studies where ≥80% of participants were aged <16 years were excluded. The flow diagram for study selection is shown in Figure 1 .
Characteristics of included studies
Thirty-six studies were included in the final synthesis: one thesis [17] and 35 journal articles [5, . The 36 studies included 11 randomized controlled studies (two crossover Figure 1 PRISMA flow diagram for the systematic review of the adverse effects of single-dose gentamicin in adults designs), 18 cohort studies, one retrospective survey, three pharmacokinetic and three quasiexperimental studies. In keeping with our background understanding and scoping searches, no existing systematic review evaluating the safety of single-dose gentamicin was identified.
Across all the included studies, 24 107 participants (male 11 107, female 11 332) received a single one-off dose of gentamicin. Ages ranged from 18 to 95 years and the dose of gentamicin ranged from 1 mg kg -1 to 480 mg. Indications for a single dose of gentamicin included prophylaxis prior to or during surgery (n = 20), cystogram (n = 1) or transrectal prostate biopsy (n = 1). It was also used to treat sepsis (n = 1), gonorrhoea (n = 3) and urinary tract infections (n = 2). Table 1 shows the characteristics of all included studies.
Risk of bias assessment
The risk of bias for each study is summarized in Figure 2 .
Monitoring and reporting of adverse events varied greatly between studies. The definition of adverse events was poorly reported, especially for older studies. Information about allocation concealment and blinding at the time of adverse event reporting was not recorded for the majority of studies.
Reporting of adverse events frequently lacked detail, making it difficult to assess the risk of bias accurately. However, most studies did provide numerical data on adverse event rates according to intervention group. Reported adverse events are summarized in Table 2 . Twenty-three [5, 19, 21, 23, 30, 33-48, 50, 51] , of the 36 included studies, reported adverse events in the gentamicin arm of their study although not all adverse events were related to gentamicin. Pons et al. [21] , the largest randomized controlled trial, had 910 participants who received ceftizoxime or gentamicin plus vancomycin as antimicrobial prophylaxis prior to neurosurgery. Adverse events were not the primary outcome, but serum creatinine and urea were measured pre-and 48 h postoperatively. There were no adverse drug reactions in the ceftizoxime group and six reactions reported in the gentamicin plus vancomycin group. All six reactions were 'significant hypotension and/or flushing', consistent with red man syndrome, a known adverse reaction associated with vancomycin. The first 186 patients enrolled into this study had a 'comprehensive review, urinalysis and serum studies' and 'there was no evidence of haematological, metabolic, hepatic or renal toxicity in either group'. Mean pretreatment serum creatinine was 79.56 μmol l -1 in the ceftizoxime group and 76.02 μmol l -1 in the gentamicin plus vancomycin group. Post-treatment mean creatinine was 73.37 and 70.72 μmol l -1 respectively. Although the paper concludes that ceftizoxime is less toxic than vancomycin plus gentamicin, this seems to be based on the adverse event data associated with vancomycin. Fried et al.
[23] compared a single dose of gentamicin with an alternative antibiotic regimen (chosen on the basis of urine culture and sensitivity testing 3 weeks earlier) given as prophylaxis prior to cystometrogram and/or cystogram. The study's main focus was clinical outcome and cost effectiveness. It was quasirandomized with patients divided into groups based on whether their medical record number ended in an odd or even number. Seventy patients were included in the oral antibiotic group and 72 in the gentamicin group, mostly treated as outpatients. No differences in adverse events were found between the two groups.
This study also asked participants in both groups to rate the comfort and convenience of treatment, on a scale of 1-5 (1 = poor and 5 = excellent). The gentamicin injection was preferable to oral antibiotics, with a mean convenience score of 4.42 in the gentamicin group compared to 3.63 in the oral antibiotic group and a mean comfort score of 4.24 in the gentamicin group compared to 3.83 in the oral antibiotic group.
Kirkcaldy et al. [5] was the most recent, large randomized controlled trial assessing single-dose gentamicin. Comprehensive monitoring for adverse events was undertaken with a high and equal frequency of adverse events in both arms of the trial. Nausea, vomiting and diarrhoea were the most commonly reported events and were attributed to azithromycin, which was given in both arms of the trial. No serious adverse events were reported over 30 days of follow-up. No specific monitoring for nephrotoxicity or ototoxicity was undertaken.
Creasey et al. [33] assessed the pharmacokinetic interaction between aztreonam and a number of other antibiotics, including gentamicin. There was one reported side effect in the gentamicin group comprising a transient rise in glutamic pyruvic transaminase, a liver enzyme.
A significant number of studies [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] have been published in the last 3 years, almost as many as in the previous 50 years. The majority of these recent studies are a form of cohort study, without randomization. Many of the studies reviewed a change in local antibiotic policies, particularly within orthopaedic surgery [35, 36, 39, 41, 43, 45, 46, 48, 50, 51] . Authors compared a cephalosporin with gentamicin plus another antibiotic, frequently flucloxacillin. The studies focused on renal impairment with little or no mention of other adverse events. It should be noted that there is a possible overlap of data between studies by Bell et al. [40] and Walker et al. [48] . Walker et al. [48] presented data from NHS Tayside, orthopaedic department between October 2008 and December 2013, which may also be included in the study by Bell et al. [40] covering five surgical specialities (including orthopaedic surgery) in NHS Tayside between October 2006 and September 2010.
Challagundlla et al. [36] divided patients into four groups: high-dose flucloxacillin plus gentamicin; low-dose flucloxacillin plus gentamicin; and two groups receiving cefuroxime (data collected retrospectively and prospectively). The dose of gentamicin was the same in both flucloxacillin groups. The study found the 'peak incidence of acute kidney injury [AKI] clearly coincides with the use of high-dose flucloxacillin with single-dose gentamicin'. Six of seven cases of renal failure (RIFLE Class F) [52] occurred in the high-dose flucloxacillin group compared with one in the low-dose flucloxacillin group.
Seventeen [19, 30, 34, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] 50 , 51] studies reported nephrotoxicity following gentamicin. A definition of nephrotoxicity or AKI was often absent or varied between studies ( Figure 2) . Where available the definition used by a particular study has been provided.
Rakovec et al. [30] included 1004 participants given either a single dose of gentamicin plus metronidazole or no antibiotics, prior to colorectal surgery. Many participants Table 1 Characteristics of included studies Craxford et al. Review of adverse effects of single-dose gentamicin (749) had a diagnosis of carcinoma and 255 had other diseases, which were not specified. Blood tests were used to monitor adverse events and a total of 38 events were reported. Nineteen patients had a transient rise in creatinine level, 13 patients had a short-lived increase in serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase, two patients had eosinophilia and four exhibited an exanthema. We have assumed that these adverse effects were seen in the antibiotic prophylaxis group, although this was not made explicit in the published article. Solgaard et al. [19] , a cohort study, compared dicloxacillin plus gentamicin to placebo as preoperative prophylaxis in patients with intertrochanteric hip fractures. This study recruited 163 patients, up to age 101 years and excluded those with preoperative creatinine >121 μmol l -1 . The study focused on nephrotoxicity, providing a clear definition of reversible and irreversible nephrotoxicity and description of how renal function was monitored. The group that received gentamicin had a median rise in creatinine, 17.2 μmol l -1 .
This was significantly greater than the placebo group, which saw no rise in creatinine. However, at day 7 postoperation, no significant difference was seen in creatinine levels compared to baseline in either the antibiotic or placebo group. One case of irreversible nephrotoxicity, defined as increasing uraemia that led to death, occurred in the gentamicin group.
No further details about this individual were given. Giri et al. [34] was one of only two randomized studies published in the last 16 years. AKI, defined as a sudden (within 48 h) decrease in renal function using Acute Kidney Injury Network Staging [53] , was reported in both groups. All patients with AKI had a normal serum creatinine at 1 month follow-up, without any further intervention. In nonrandomized studies by Craig et [45] renal function returned to normal by the end of the follow up period. Bailey et al. [41] reported 24 (9.4%) episodes of AKI [54] , of which 21 had resolved at 7 days postoperation. Two of the three patients whose AKI persisted had normal creatinine at 28 days and 32 days. The third patient was lost to follow-up, but had normal creatinine at 23 months. Cobussen et al. [47] compared creatinine on and after admission, as well as between the gentamicin and control groups. After admission, there was no difference in the incidence and severity of AKI between the gentamicin and control groups. At 8-14 days after admission most patients returned to their baseline creatinine. Ahmed et al. [46] reported that of those who developed AKI [55] postoperatively, 80% of those in the gentamicin group and 79% in the cefuroxime group had resolution prior to discharge. Dubrovskaya et al. [45] reported that 76.9% of patients with nephrotoxicity [54] in the gentamicin group and 82.6% in the control group had a creatinine within normal limits at the time of discharge (P = 0.703). Sprowson et al. [39] found that many of their participants had a transient rise in creatinine but in their analysis the authors only included participants with acute renal failure requiring High Dependency Unit (HDU) admission. Although the numbers were small in Figure 2 Risk of bias assessment of included studies Cobussen et al. Reversible AKI (5) Not reversible AKI (3) Craxford et al. AKI by RIFLE R = (9) I + F = (7)
Craxford [42] et al. Review of adverse effects of single-dose gentamicin Nielson et al. Sundman et al. Review of adverse effects of single-dose gentamicin both groups, there was a significant difference in the frequency of HDU admission between patients who received gentamicin (0.33%) and those who received cefuroxime (0.07%; P < 0.01. [38] and Nielson et al. [44] analysed creatinine between 24-72 h postoperatively and Ross et al. [51] performed their evaluation immediately postoperatively. None of these studies provided data beyond 4 days after treatment. Both studies by Nielson et al. [37, 44] reported no statistically significant difference in the frequency of postoperative dialysis and in one [44] , there was no difference in the median maximum serum creatinine after 72 h.
Bell et al. [40] , the largest cohort, study identified and assessed the risk of AKI in patients receiving antibiotic prophylaxis before surgery, across five different surgical specialities. Unfortunately, data and publication errors in the descriptive data tables make it difficult to interpret the original data. The study reports an increase in rates of AKI in patients receiving gentamicin who underwent orthopaedic surgery, with the majority of AKI being transient Stage 1 [56] . There was no association between AKI and gentamicin in urology, vascular, gastrointestinal or gynaecology surgical patients. The same NHS Trust also published Walker et al. [48] , the second largest cohort study. This assessed postoperative AKI in patients who had neck of femur repair operations or other orthopaedic surgery. For this review, we included only data provided for patients undergoing orthopaedic surgery other than neck of femur repair, as only this group received a single dose of gentamicin. The majority (83%) of AKI seen in both treatment groups was Stage 1 [56] , with 9.86% reported in the gentamicin group and 8.03% in the co-amoxiclav comparison group. Similar small differences were also seen in rates of Stage 2 and 3 AKI. There is no comment on whether these differences were statistically significant but the authors suggest that changes in practice, such as anaesthetic technique and postoperative care may have contributed to the differences seen.
Craxford et al. [43] found a statistically significant increase in AKI [54] between elective lower limb arthroplasty patients who received gentamicin plus flucloxacillin, compared to those who received cefuroxime (P < 0.01) but there was no significant difference in the frequency of haemofiltration between the groups. The difference in rates of AKI appeared to be independent of potential confounders and was not seen in a subgroup analysis of patients undergoing different surgical procedures. AKI was commoner in the total knee replacement group, but not in the total hip replacement group, which might be related to the use of a pneumatic tourniquet in the total knee replacement group.
Subgroup analysis
In studies where all participants were aged <75 years, there were no reported episodes of nephrotoxicity or rise in creatinine. In studies where a fixed dose of ≤240 mg of gentamicin was given, four out of 14 studies reported higher frequency of nephrotoxicity or a rise in creatinine in the gentamicin group. Of the 11 randomized controlled trials, only one study reported nephrotoxicity in the gentamicin arm and this was not statistically significant. Twenty studies used gentamicin as a surgical prophylaxis, of which 17 reported either nephrotoxicity or a rise in creatinine in the gentamicin arm. This compares to one study out of the 16 that used gentamicin for another indication.
No meta-analysis was undertaken due to heterogeneity of the studies in relation to wide variations in patient demographics, comorbidities, doses of gentamicin, study design and reporting of adverse events.
Discussion
Our systematic review suggests that single-dose gentamicin can have an effect on renal function, but this is usually mild and/or transient. In the 36 studies identified, there were 2599 episodes of creatinine rise or nephrotoxicity in the gentamicin group. However, many cases resolved within a few days or weeks or occurred in populations with renal risk factors. No cases of ototoxicity were reported.
Our findings are in keeping with existing knowledge of gentamicin and its side effects, which is based on multiple dosing regimens. Nephrotoxicity is considered to be dose related [57] . Reuptake of the drug occurs in the proximal renal tubule where it leads to high drug concentrations within the tubule cells [58] . The risk of nephrotoxicity can be minimized by serum-level monitoring with dose adjustment, and shortening the duration of treatment [59] . Several risk factors are thought to predispose to nephrotoxicity including increasing age, pre-existing renal disease, use of diuretics, exposure to radiographic contrast, circulating volume depletion and use of other nephrotoxic medication including angiotensin-converting enzyme inhibitors, Nonsteroidal anti-inflammatory drugs, amphotericin or cisplatin [11, [60] [61] [62] . In multiple dosing of gentamicin, the frequency of related nephrotoxicity is reported to be 10-25% [63] [64] [65] .
Although no episodes of ototoxicity were reported in our review, gentamicin is primarily vestibulotoxic [66] , causing damage to the vestibular apparatus, initially affecting the cristae and progressing to the striolar regions of the maculi [67] . Clinically, this leads to dizziness, ataxia and nystagmus. Destruction of the auditory sensory cells of the organ of Corti leads to cochleotoxicity, which is associated with overproduction of oxidative free radicals [68] and can present as hearing loss or tinnitus. In our review, Kirkcaldy et al. [5] was the only study to report seven episodes of dizziness in the gentamicin group, but an equal number of episodes were reported in the comparator group. The ototoxicity of aminoglycosides, which is irreversible, does not correlate with drug levels in the fluid of the inner ear, drug dose or gentamicin serum concentration [69, 70] . In a study of 30 patients with gentamicin associated vestibulotoxicity, 16 had received less than the recommended maximum dose of 5 mg kg -1 day -1 over 10 days [70] . A review of aminoglycoside toxicity including papers published between 1975 and 1982 identified eight studies (559 patients) that evaluated gentamicin [71] and found the frequency of vestibulotoxicity to be 2.7%, and of cochlear toxicity 8.3% [71] . A subsequent review in 2008, using different inclusion criteria, assessed four additional studies (147 patients) and found a frequency of vestibulotoxicity of 10.9% 1 week after completing treatment [72] . This review did not comment on cochlear toxicity and neither review assessed the effect of duration of therapy on risk of ototoxicity. In a case series of 33 patients with permanent gentamicin-induced vestibulotoxicity, one patient had developed vestibular toxicity after 5 days of treatment; all other patients had received a longer course of gentamicin [73] . In a larger case series, six of 103 patients presenting to a balance disorder clinic with a diagnosis of severe, symmetrical, selective, bilateral vestibular loss, had received only a single dose of gentamicin [72] . The lack of correlation between drug dose or serum concentration in causing vestibular or cochlear toxicity makes it difficult to predict which patients will be affected. Increasing age [74] and a mitochondrial DNA mutation, (m.1555A>G) [75, 76] , have both been shown to increase a patient's susceptibility to cochleotoxicity, but not vestibulotoxicity.
The main strength of this systematic review was a robust search strategy and adherence to established protocols published by the Cochrane group [12] and Center for Reviews and Dissemination at University of York [77] . This minimized the risk of excluding a potentially relevant study. Limiting the analysis to studies that had a comparator group provided a more robust evaluation of the adverse effects that were associated with gentamicin.
Many of the limitations of this review are in part due to the design or reporting of included studies. It would have been preferable to have reported a meta-analysis, but heterogeneity of the studies meant this would have been inappropriate. In patients receiving multiple interventions, it can be difficult to identify the relative contribution of a single agent to reported adverse effects. In particular, other factors such as concomitant medication, pre-existing comorbidities and surgical procedures can affect the risk of kidney injury. In our review, the studies [39-41, 43, 46, 48] that reported a statistically significant increase in AKI were all carried out in patients undergoing orthopaedic surgery. It is likely that patients are more vulnerable to the renal effects of gentamicin if they are older or are taking nonsteroidal anti-inflammatory drugs for joint pain.
Cohort studies contributed the largest proportion of data to the review with an associated risk of unidentified confounding factors leading to bias. The majority of studies used antibiotic combination regimens, again making it difficult to identify the specific role of gentamicin. Flucloxacillin alone is not a common cause of nephrotoxicity, but Challagundlla et al. [36] reported a difference in AKI between high-and low-dose flucloxacillin groups when all other confounders were accounted for. Whether flucloxacillin has a synergistic effect to cause gentamicin toxicity is unclear, but studies with adjunctive antibiotics need to be interpreted with caution. Only one study [39] published after 1996 did not use an adjunctive antibiotic in combination with gentamicin.
The quality of studies was generally poor, specifically in defining and reporting adverse events, and especially for studies reporting prior to 2012. The risk of bias was therefore high or uncertain for many studies. Reporting of adverse events was often limited to one or two sentences commenting on a lack of side effects. These limited data on adverse events also make it difficult to identify specific subgroups that might be at higher risk of toxicity. Poor reporting of adverse events is a common problem even in otherwise high-quality trials [19, 20] . We were also unable to obtain 47 (5%) of the 933 potentially relevant reports. The majority (n = 38) of these were conference abstracts, proceedings, dissertations or theses. Thirty of these 47 records also lacked a published abstract.
A relatively new indication for gentamicin is for the treatment of gonorrhoea. Gonorrhoea has been increasing in men and women in England since 2010, with a 21% increase between 2014-15 [78] . Multidrug resistance is common and an outbreak of highly level resistance to azithromycin was recently reported in England [79] . The World Health Organization has listed Neisseria gonorrhoeae as a high priority pathogen for research and development of new antibiotics [80] . Two systematic reviews have showed that single-dose gentamicin is an effective treatment [4, 6] and this has been supported by a large clinical trial [5] . This systematic review supports the use of single-dose gentamicin as a safe alternative treatment for gonorrhoea.
Previous reports have found that repeated single daily dosing of aminoglycosides has an equivalent or lower level of toxicity compared to multiple daily doses [11] . Other antimicrobials have also shown an improved side effect profile when used as single-dose daily therapy [81] but our review is the first to assess the toxicity of a single, one-off, dose of gentamicin.
